Kerstein

Latest articles

14d
Breitbart
Minnesota High School Requires English Course Aimed at Destroying ‘White Privilege’“Edina citizens should hold district leaders accountable for substituting polit
Breitbart / Posted 14 days ago
“Edina citizens should hold district leaders accountable for substituting political indoctrination for a real education.” Kerstein and the Minnesota-based Center for the American Experiment began looking into the teaching practices of Edina High... Read more
2 related articles
22d
WAVE 3 Louisville
40 things to know ahead of the Churchill Downs fall meetThe weekly one-hour horse racing radio show is co-hosted by Churchill Downs Rac
WAVE 3 Louisville / Posted 22 days ago
The weekly one-hour horse racing radio show is co-hosted by Churchill Downs Racetrack’s John Asher, Darren Rogers and Kevin Kerstein, and delivers a wide-ranging list of interesting guests, from jockeys, trainers, owners to well-informed... Read more
8 related articles
1m
Business Wire
武田呈報ALUNBRIGTM (brigatinib)治療ALK陽性非小細胞肺癌樞紐性2期ALTA試驗的更新結果90毫克每日一次(n=112;90毫克;A組)或7天導入期90毫克每日一次、然後180毫克每日一次(n=110;180毫克;B組)。 武田腫瘤臨床研究部資深
Business Wire / Posted a month ago
90毫克每日一次(n=112;90毫克;A組)或7天導入期90毫克每日一次、然後180毫克每日一次(n=110;180毫克;B組)。 武田腫瘤臨床研究部資深醫學總監、ALUNBRIG全球臨床負責人David Kerstein,... Read more
40 related articles
1m
Business Wire
武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果90毫克每日一次(n=112;90毫克;A组)或7天导入期90毫克每日一次、然后180毫克每日一次(n=110;180毫克;B组)。 武田肿瘤临床研究部高级
Business Wire / Posted a month ago
90毫克每日一次(n=112;90毫克;A组)或7天导入期90毫克每日一次、然后180毫克每日一次(n=110;180毫克;B组)。 武田肿瘤临床研究部高级医学总监、ALUNBRIG全球临床负责人David Kerstein,... Read more
40 related articles
m
Business Wire
Takeda präsentiert aktualisierte Ergebnisse aus zulassungsrelevanter Phase-Studie ALTA zu ALUNBRIGTM (Brigatinib) bei ALK-positivem, nicht-kleinzelligem Lungenkrebsvon ALUNBRIG bei der Behandlung von Patienten mit fortgeschrittenem ALK-positiv
Business Wire / Posted 1 months ago
von ALUNBRIG bei der Behandlung von Patienten mit fortgeschrittenem ALK-positivem NSCLC weiter untermauern“, sagte David Kerstein, M.D., Senior Medical Director und Global Clinical Lead für ALUNBRIG, Oncology Clinical Research, Takeda. „Es... Read more
601 related articles
m
Business Wire
Takeda présente les résultats mis à jour de l'essai pivot ALTA de Phase 2 pour l'ALUNBRIGTM (brigatinib) contre le cancer du poumon non à petites cellules ALK positifdes preuves soutenant le rôle de l'ALUNBRIG dans le traitement de patients atte
Business Wire / Posted 1 months ago
des preuves soutenant le rôle de l'ALUNBRIG dans le traitement de patients atteints de CPNPC ALK+ avancé", déclare David Kerstein, D.M., directeur médical et responsable clinique pour l'ALUNBRIG, du service de recherche clinique en oncologie de... Read more
331 related articles
m
New Kerala
Takeda Presents Updated Results from Pivotal Phase 2 ALTA Trial of ALUNBRIG (brigatinib) in ALK-Positive Non-Small Cell Lung Cancer - newkerala news #281017further evidence supporting the role of ALUNBRIG in the treatment of patients w
New Kerala / Posted 1 months ago
further evidence supporting the role of ALUNBRIG in the treatment of patients with advanced ALK-positive NSCLC," said David Kerstein, M.D., Senior Medical Director and Global Clinical Lead for ALUNBRIG, Oncology Clinical Research, Takeda. "There... Read more

In this news